Abstract
Early CoVID-19 growth obeys: , with Ko = [(ln 2)/(tdbl)], where tdbl is the pandemic growth doubling time. Given , the daily number of new CoVID-19 cases is . Implementing society-wide Social Distancing increases the tdbl doubling time, and a linear function of time for tdbl was used in our Initial Model: to describe these changes, with Go = [KA/γo]. However, this equation could not easily model some quickly decreasing ρ[t] cases, indicating that a second Social Distancing process was involved. This second process is most evident in the initial CoVID-19 data from China, South Korea, and Italy. The Italy data is analyzed here in detail as representative of this second process. Modifying Zo[t] to allow exponential cutoffs: provides a new Enhanced Initial Model (EIM), which significantly improves datafits, where . Since large variations are present in ρdata [t], these models were generalized into an orthogonal function series, to provide additional data fitting parameters:
Its first term can give No[t] or NE [t], for Z[t] → Zo[t] or Z[t] → Ze[t]. The Lm(Z) are Laguerre Polynomials, with L0(Z) = 1, and {gm; m = 0,MF} are constants derived from each dataset. When ρ[t] = dN[t]/dt gradually decreases, using Zo[t] provided good datafits at small MF values, but was inadequate if ρ[t] decreased faster. For those cases, ZE[t] was used in the above N(Z) series to give the most general Enhanced Orthogonal Function [EOF] model developed here. Even with MF = 0, qo = 0, this EOF model fit the Italy CoVID-19 data for ρ[t] = dN[t]/dt fairly well.
When the ρ[t] post-peak behavior is not Gaussian, then ZE[t] with δo ≠ 0, qo = 0; which we call ZA[t], is also likely to be a sufficient extension of the Zo[t] model. The EOF model also can model a gradually decreasing ρ[t] tail using small {δo, qo} values [with 6 Figures].
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No External Funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No Human Subjects Involved in this Data Analysis. No IRB approval needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used is in the public domain or was on the CoVID-19 website maintained by bing.com.